Actually, It's Not About The Patient – At Least When It Comes To Product Exclusivity
Executive Summary
Otsuka sues FDA for allowing Alkermes' ‘chemical trick’ to skirt Abilify Maintena's exclusivity, but agency says active moieties of the two drugs are not the same, regardless how they behave in patients.
You may also be interested in...
FDA Wins Abilify Exclusivity Battle; Court Rejects Otsuka's 'Legal Equivalence'
Otsuka claimed Alkermes' Aristada is 'legally equivalent' to Abilify but DC Circuit deferred to FDA's finding that the two have different active moieties and thus Abilify's three-year exclusivity does not apply to Aristada.
Score Five For FDA: Shire's Vyvanse Entitled To NME Exclusivity, Court Finds
FDA scored a victory when a district court ruled that it was correct in awarding five years of market exclusivity to Shire's attention-deficit hyperactivity disorder drug Vyvanse (lisdexamfetamine)
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.